301 related articles for article (PubMed ID: 16808259)
21. [Secondary amyloidosis in rheumatoid arthritis. A clinical study of 29 patients].
Fiter Aresté J; Nolla Solé JM; Gómez Vaquero C; Valverde García J; Roig Escofet D
An Med Interna; 1999 Dec; 16(12):615-9. PubMed ID: 10686712
[TBL] [Abstract][Full Text] [Related]
22. [Laboratory findings and serum levels of amyloid A and soluble interleukin-2 receptors in patients with renal amyloidosis].
Rysavá R; Merta M; Tesar V; Zabka J; Spicka I; Stejskalová A; Vernerová Z
Cas Lek Cesk; 1998 Feb; 137(4):107-9. PubMed ID: 9531732
[TBL] [Abstract][Full Text] [Related]
23. Secondary systemic amyloidosis: response and survival in 64 patients.
Gertz MA; Kyle RA
Medicine (Baltimore); 1991 Jul; 70(4):246-56. PubMed ID: 2067409
[TBL] [Abstract][Full Text] [Related]
24. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis.
Nakamura T; Higashi S; Tomoda K; Tsukano M; Baba S; Shono M
Rheumatology (Oxford); 2006 Jan; 45(1):43-9. PubMed ID: 16219644
[TBL] [Abstract][Full Text] [Related]
25. Renal Behçet's disease: an update.
Akpolat T; Dilek M; Aksu K; Keser G; Toprak O; Cirit M; Oğuz Y; Taşkapan H; Adibelli Z; Akar H; Tokgöz B; Arici M; Celiker H; Diri B; Akpolat I
Semin Arthritis Rheum; 2008 Dec; 38(3):241-8. PubMed ID: 18221990
[TBL] [Abstract][Full Text] [Related]
26. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
[TBL] [Abstract][Full Text] [Related]
27. [Secondary systemic amyloidosis A combined with primary glomerulonephritis and systemic diseases].
Bogov B; Kiperova B; Dzherasi R; Andreev E; Minkova V
Vutr Boles; 1999; 31(1):19-22. PubMed ID: 10847144
[TBL] [Abstract][Full Text] [Related]
28. Ten years' experience of an amyloid clinic--a clinicopathological survey.
Browning MJ; Banks RA; Tribe CR; Hollingworth P; Kingswood C; Mackenzie JC; Bacon PA
Q J Med; 1985 Mar; 54(215):213-27. PubMed ID: 3991877
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of thirty-four rheumatoid arthritis patients with renal amyloidosis, including twelve given alkylating agents.
Couverchel L; Maugars Y; Prost A
Rev Rhum Engl Ed; 1995 Feb; 62(2):79-85. PubMed ID: 7600076
[TBL] [Abstract][Full Text] [Related]
30. Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics.
Berglund K; Thysell H; Keller C
J Rheumatol; 1993 Dec; 20(12):2051-7. PubMed ID: 8014932
[TBL] [Abstract][Full Text] [Related]
31. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
Eirin A; Irazabal MV; Gertz MA; Dispenzieri A; Lacy MQ; Kumar S; Sethi S; Nasr SH; Cornell LD; Fidler ME; Fervenza FC; Leung N
Nephrol Dial Transplant; 2012 Mar; 27(3):1097-101. PubMed ID: 22067518
[TBL] [Abstract][Full Text] [Related]
32. Hereditary systemic amyloidosis with renal involvement.
Hawkins PN
J Nephrol; 2003; 16(3):443-8. PubMed ID: 12832750
[TBL] [Abstract][Full Text] [Related]
33. Decreasing incidence of AA amyloidosis in Spain.
Panizo N; Rivera F; López-Gómez JM;
Eur J Clin Invest; 2013 Aug; 43(8):767-73. PubMed ID: 23683125
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical analysis of transforming growth factor beta-1 in AA and AL renal amyloidosis.
Danilewicz M; Wagrowska-Danilewicz M
Pol J Pathol; 2006; 57(4):193-8. PubMed ID: 17285762
[TBL] [Abstract][Full Text] [Related]
35. The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever.
Sahin S; Sahin GM; Ergin H; Kantarci G
Ren Fail; 2007; 29(3):315-9. PubMed ID: 17497446
[TBL] [Abstract][Full Text] [Related]
36. [Systemic amyloidosis with renal involvement].
Jankovec Z; Rusavý Z; Tĕsínský P; Lacigová S
Cas Lek Cesk; 1999 Nov; 138(22):699-700. PubMed ID: 10746031
[TBL] [Abstract][Full Text] [Related]
37. [Calcific uraemic arteriolopathy (calciphylaxis): incidence, clinical features and long term outcomes].
Esteve V; Almirall J; Luelmo J; Sáez A; Andreu X; García M
Nefrologia; 2007; 27(5):599-604. PubMed ID: 18045036
[TBL] [Abstract][Full Text] [Related]
38. [Amyloidosis AA].
Stankovic K; Grateau G
Nephrol Ther; 2008 Jul; 4(4):281-7. PubMed ID: 18514052
[TBL] [Abstract][Full Text] [Related]
39. Does renal function influence plasma levels of advanced glycation and oxidation protein products in patients with chronic rheumatic diseases complicated by secondary amyloidosis?
Rysavá R; Kalousová M; Zima T; Dostál C; Merta M; Tesar V
Kidney Blood Press Res; 2007; 30(1):1-7. PubMed ID: 17191033
[TBL] [Abstract][Full Text] [Related]
40. Longterm outcome of amyloidosis associated with juvenile idiopathic arthritis.
Immonen K; Savolainen A; Kautiainen H; Hakala M
J Rheumatol; 2008 May; 35(5):907-12. PubMed ID: 18381779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
